August 4, 2021 – RedDress, a privately held U.S. and Israel-based wound care company, secured a contract with Capstone Health Alliance.
Chronic non-healing wounds impose a significant economic burden on the healthcare system, health care providers, and patients. RedDress’ ActiGraft system aims to deliver an affordable and efficacious wound solution to Capstone Health Alliance Members to help improve the health and lives of patients.
The company says that ActiGraft is the first wound care product that enables healthcare providers to produce—in real time— an in vitro blood clot from a patient’s own blood. Once applied, the blood clot serves as a protective covering and supports the body’s natural wound healing response.
ActiGraft can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds and post-surgical wounds.
RedDress was awarded contract number # CAP-MM-146.
Capstone Health Alliance is one of the nation’s largest regional group purchasing organizations representing around 300 hospitals in all 50 U.S. states.